featured
Eprenetapopt and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
J. Clin. Oncol 2021 Jan 15;[EPub Ahead of Print], DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, MA Sekeres, T Cluzeau, KL Sweet, A McLemore, KL McGraw, J Puskas, L Zhang, J Yao, Q Mo, L Nardelli, NH Al Ali, E Padron, G Korbel, EC Attar, HM Kantarjian, JE Lancet, P Fenaux, AF List, RS KomrokjiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.